#USA #New York #Class Action #Securities Fraud #Vistagen Therapeutics

Urgent Notice for Vistagen Therapeutics Investors

In a significant development for investors, Levi & Korsinsky, LLP is urging shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) to consider joining a class action lawsuit designed to address potential losses attributed to alleged securities fraud. The case focuses on a time period between April 1, 2024, and December 16, 2025, during which the company's statements and actions are said to have misled investors.

What is the Class Action About?

The lawsuit aims to represent those who have suffered financial losses due to misleading information presented by Vistagen regarding its clinical trial results for fasedienol, a drug under investigation for treating social anxiety disorder. Despite issuing positive statements about the Phase 3 PALISADE-3 trial, the company later revealed disappointing results, significantly impacting its stock price.

On December 17, 2025, Vistagen disclosed that the PALISADE-3 study failed to show statistically significant improvements in its primary outcomes, leading to an extraordinary drop in the company's stock value—plummeting from $4.36 per share down to $0.86 in just one day, a fall of over 80%. This dramatic decline raises alarms about the integrity of the information provided to shareholders.

Why You Should Consider Joining

Investors who believe they have incurred losses linked to Vistagen's actions during the specified timeframe have until March 16, 2026, to express their intent to become lead plaintiffs in this crucial lawsuit. Taking part in this class action may not only provide a pathway to potential compensation but also hold the company accountable for its decisions that misled investors.

Participation in the lawsuit carries no financial risk, as class members may be entitled to compensation without any out-of-pocket fees. Joining the suit could be an opportunity for shareholders to reclaim some of their losses without upfront costs, making it a compelling option for those affected.

Levi & Korsinsky's Track Record

With over two decades of experience, Levi & Korsinsky has earned a reputation for advocating on behalf of shareholders and successfully obtaining substantial settlements in securities litigation. Their expertise and dedicated team, consisting of over 70 professionals, make them a formidable representative for investors seeking redress.

The firm has consistently ranked among the top securities litigation firms in the United States, indicating their capabilities in handling complex cases with significant stakes. They are well-versed in the intricacies of securities law and are committed to protecting investors' rights.

Contact Information

For those interested in participating, you are encouraged to reach out to Levi & Korsinsky. You can complete a submission form to receive more information or contact the attorneys directly:

• - Email: [email protected]
• - Phone: (212) 363-7500

This is a crucial moment for Vistagen investors to act decisively. Don’t miss the opportunity to join this class action lawsuit, which could potentially help you recover your losses and seek accountability for the actions taken by the company.

• ---

Stay informed and engaged, as developments continue to unfold in this significant matter involving Vistagen Therapeutics.